NMN Side Effects: The Science vs the Hype in 2026

Short-term tolerability is the best-documented fact about NMN. Long-term safety is the least.

Presented By Our Partners

In a 2026 meta-analysis of 15 randomized trials, oral NMN at 250 to 2,000 mg per day for 14 days to 24 weeks did not increase overall adverse events, serious adverse events, withdrawals due to adverse events, or the liver enzymes ALT and AST compared with control (PMID 42514320). That is a reassuring result and Healthcare Discovery grades the tolerability claim as moderate evidence, scoring it 33 out of 100 on the HYPE Index, largely calibrated. The reason it is not graded strong, and the reason the HYPE score is not lower, is in the duration column. No NMN trial has run longer than 24 weeks, and most ran 4 to 12. The market reads six months of tolerability as lifelong safety. No trial has examined that.

What the trials reported

The pattern is consistent across doses that span nearly a tenfold range. At 250 mg per day, the dose most trials used, 12 and 24-week trials in older adults reported nothing beyond placebo. At 1,250 mg per day for a month in healthy adults, standard blood chemistry did not move. At 2,000 mg per day for a month in overweight adults, the pharmaceutical-grade MIB-626 formulation matched placebo on adverse events. Liver enzymes, the usual early warning for a supplement metabolized in the liver, either held steady or drifted slightly downward.

The signals worth knowing about

Two findings do not fit the clean picture and deserve to be named. First, in 11 non-athletic young men, 7 days of NMN at 1,200 mg per day suppressed exercise-induced inflammatory gene expression but also delayed clearance of infiltrating cells from damaged muscle and abolished the 171 percent increase in mitochondrial content seen 24 hours after exercise with placebo (PMID 41705654). This is a mechanistic biopsy result in a tiny crossover, not a clinical adverse event, but it suggests NMN may interfere with a beneficial training adaptation. Second, a post hoc analysis of the 80-person dose-ranging trial found that higher baseline blood NAD was associated with slightly higher triglycerides, lower HDL and higher ALT and AST, and that NMN-induced NAD increases were associated with small rises in hemoglobin and red cell count (PMID 41162813). The associations are tiny (hemoglobin up 0.027 percent per nM of NAD) and correlational, so they do not establish harm, but they are the kind of signal a longer trial would need to track.

The theoretical concerns are older and larger. A 2020 systematic review of 147 articles on NAD precursors, 113 of them preclinical, listed potential risks of toxic metabolite accumulation, tumorigenesis and cellular senescence with chronic NAD elevation (PMID 31917996). NAD is a cofactor for rapidly dividing cells, and some tumor models grow faster with more of it. Every published NMN trial excluded people with cancer, which means the population with the most at stake has no safety data at all.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

What we do not know

Safety beyond 24 weeks, in anyone. Safety in people with active cancer or a cancer history. Safety in pregnancy, breastfeeding, childhood and adolescence, liver disease and kidney disease, all of which were excluded from every trial. Interactions with chemotherapy, with NAMPT inhibitors in development, and with the sirtuin activators NMN is often stacked with. Whether stacking NMN with niacin, nicotinamide or nicotinamide riboside, all of which feed the same NAD pool, raises methylated nicotinamide metabolites to a level that matters (PMID 31685720). And whether the mitochondrial finding in exercisers replicates in trained adults over longer periods. Who ran the safety trials is the last open question. According to PubMed author affiliations, the 1,250 mg safety trial had authors from Mitsubishi Corporation Life Sciences (PMID 36002548), both MIB-626 trials had authors from its developer, Metro International Biotech (PMID 36740954; PMID 35182418), the 24-week trial had authors from Teijin and NOMON (PMID 36443648), and the 12-week trial in older adults had authors from Meiji Holdings (PMID 38789831). The 80-person trial behind the post hoc blood findings was co-sponsored by ABA Chemicals and Abinopharm, the companies that made its NMN (PMID 36482258). Company involvement does not make a safety result wrong, but most of the individual safety record comes from trials with company-affiliated authors.

Doses used in studies

These are doses reported by the named sources, not recommendations.

The full interaction table, including the condition rows for cancer, pregnancy and surgery, is in Healthcare Discovery’s NMN evidence review. The related precursor is compared at NMN vs Nicotinamide Riboside, and the scoring method is at HYPE Index methodology.

Compiled by Healthcare Discovery from the cited PubMed studies. Every citation, author affiliation and trial sponsor named on this page was checked against PubMed on October 27, 2026. How claims are scored: HYPE Index methodology.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.

Keep Reading on Healthcare Discovery

• Muscle Is a Longevity Organ: What the Science of Strength Training Reveals About All-Cause Mortality
• The Daily Rounds: Longevity & Health Care Brief | May 27, 2026
• Google Nest Hub 2nd Gen: Radar-Based Sleep Tracking in a Smart Display